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Degenerative joint disease and associated pain are common in cats, particularly in older
cats. There is a need for treatment options, however evaluation of putative therapies is lim-
ited by a lack of suitable, validated outcome measures that can be used in the target popula-
tion of client owned cats. The objectives of this study were to evaluate low-dose daily
meloxicam for the treatment of pain associated with degenerative joint disease in cats, and
further validate two clinical metrology instruments, the Feline Musculoskeletal Pain Index
(FMPI) and the Client Specific Outcome Measures (CSOM).
Methods
Sixty-six client owned cats with degenerative joint disease and owner-reported impairments
in mobility were screened and enrolled into a double-masked, placebo-controlled, random-
ized clinical trial. Following a run-in baseline period, cats were given either placebo or
meloxicam for 21 days, then in a masked washout, cats were all given placebo for 21 days.
Subsequently, cats were given the opposite treatment, placebo or meloxicam, for 21 days.
Cats wore activity monitors throughout the study, owners completed clinical metrology
instruments following each period.
Results
Activity counts were increased in cats during treatment with daily meloxicam (p<0.0001)
compared to baseline. The FMPI results and activity count data offer concurrent validation
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for the FMPI, though the relationship between baseline activity counts and FMPI scores at
baseline was poor (R2=0.034). The CSOM did not show responsiveness for improvement in
this study, and the relationship between baseline activity counts and CSOM scores at base-
line was similarly poor (R2=0.042).
Conclusions
Refinements to the FMPI, including abbreviation of the instrument and scoring as percent of
possible score are recommended. This study offered further validation of the FMPI as a clin-
ical metrology instrument for use in detecting therapeutic efficacy in cats with degenerative
joint disease.
Introduction
Many adult and geriatric cats suffer from Degenerative Joint Disease (DJD) and associated
chronic pain.[1, 2] In the United States, there is no approved medication for the long-term
treatment of chronic pain in cats, despite the clear need for such a treatment. Several factors
impair the ability to find useful treatment options for cats with DJD, including the lack of clini-
cally-applicable, validated screening tools to identify cats with DJD-associated mobility
impairment and outcome measures to evaluate efficacy of therapeutics.
Diagnosis of DJD has historically relied on some combination of veterinary examination,
radiographic evidence, and owner input.[3–6] Previously, our group developed an instrument,
the Feline Musculoskeletal Pain Index (FMPI),[7–9] to address this need. In the current study,
we further investigated the function and use of the FMPI, including its ability to detect improve-
ment using the non-steroidal anti-inflammatory, meloxicam, as a therapeutic intervention.
Meloxicam is used commonly in veterinary medicine for the treatment of DJD-associated
chronic pain in dogs.[10–12] Meloxicam is currently approved in Europe for use in treating
chronic pain in cats, but has not been approved for this use in the United States. There have
been several suggestions from open label studies that lower doses of meloxicam than that
approved in Europe are effective in the management of feline DJD-associated pain.[13, 14]
The purposes of the current study were two-fold: to evaluate the effectiveness of a ‘low dose’
of oral meloxicam to improve mobility in cats with DJD-associated chronic pain as measured
by actimetry (a non-invasive method to monitor activity), and to further refine and validate
the FMPI and other outcome measures. The additional outcome measures included a clinical
metrology instrument we have termed the Client Specific Outcome Measure (CSOM),[15]
fashioned after the Cincinnati Orthopedic Disability Index described for use in dogs,[16] and
owner assessments of quality of life and temperament. Recently, we reported that owners may
be better able to discriminate withdrawal of active medication than withdrawal of placebo, and
that return of clinical signs following a treatment period might be a useful measure of efficacy.
[17] This approach was also included in the data presented here.
We hypothesized that a low-dose of oral meloxicam given once daily would increase activity
counts in cats as measured by actimetry and that activity counts would significantly decrease
following withdrawal of meloxicam. Further, we hypothesized that the FMPI and the CSOM
would respond to treatment, and/or withdrawal of treatment, and show criterion validity with
the actimetry measures. Specifically, we tested the responsiveness (ability to detect the effect of
an analgesic treatment and ability to detect the withdrawal of an analgesic) of the FMPI and
CSOM in a double-masked, cross-over, placebo-controlled study and concurrently evaluated
CMIs for DJD in Cats
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their criterion validity (whether the changes detected by the instrument correlated with an
objective measure of altered mobility) by objectively measuring changes in activity counts in
cats with DJD-associated pain.
Materials and Methods
This study was approved by the Animal Care and Use Committee (Protocol # 11-102-O), at
North Carolina State University College of Veterinary Medicine (NCSU-CVM), and written
owner consent was granted in each case following verbal discussion of the study. The reporting
of data follows the CONSORT guidelines.[18]
Study Design
This was a randomized, stratified, double masked, placebo controlled, crossover clinical trial.
Outcome measures included changes in owner ratings as well as changes in activity (as mea-
sured by actimetry) after having been treated with the active drug or placebo. Additionally,
adverse events and clinical pathology were outcome measures.
Animals
Potential study subjects were identified from clinic records by area primary care veterinarians,
or were self-referred by owners that had seen advertisements for the clinical trial. Animals
enrolled in the study were all client owned animals with naturally occurring chronic musculo-
skeletal disease.
Inclusion and Exclusion Criteria
Cats were eligible to participate in the study if they had a qualifying degree of owner-noted
mobility/activity impairment (described in the next section), evidence of pain during manipula-
tion of at least two joints or spinal segments during veterinary orthopedic evaluation (described
below underOrthopedic evaluation), and radiographic evidence of degenerative joint disease in
at least two of the painful joints or spinal segments (described below under Radiographic evalu-
ation). Cats also had to be greater than 1 year of age and weigh more than 1 kg (2.2 pounds).
Predetermined exclusion criteria for all cats included the presence of suspected or diagnosed
infectious diseases, symptomatic cardiac disease, immune-mediated disease, neoplasia, inflam-
matory bowel disease, urinary tract infection, hyperthyroidism, and diabetes mellitus. These
conditions were ruled out by careful review of the medical records, owner history, physical
examination, complete blood count (CBC), serum biochemistry panels, and urinalysis. Cats
with chronic kidney disease (CKD) up to and including IRIS stage 2 [19] were eligible to enroll,
provided the disease was stable as determined by repeated serum biochemistry panels and uri-
nalyses. Cats with CKD of IRIS stage 3 or 4 were excluded from the study.
Owner Evaluation of Mobility Impairment
During the screening interview, owners were asked to identify three activities that their cat
showed impairment in performing. All interviews were carried out by either the study veteri-
narian (MG) or the study research technician (AT) who worked together to ensure uniform cli-
ent interviews. Suggestions of types of activities were given to owners (e.g., running, jumping
up to a specified height, moving up or down stairs) but owners were encouraged to generate
activities specific to their cat. The investigator recommended that the activity be something
that the owner felt the cat would be able to perform again if pain was controlled. These three
items were then used to construct the Client Specific Outcome Measures (CSOM) assessment
CMIs for DJD in Cats
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described below, and used for future assessments if the cats were successfully enrolled. Owners
rated their cat’s ability to perform each activity on a Likert type scale ranging from 4 (No Prob-
lem) to 0 (Impossible) with intermediate values of 3 (Mild difficulty), 2 (Moderate difficulty),
and 1 (Severe difficulty). Owner ratings were converted to numerical scores, and total CSOM
score represented the sum of these three scores with a possible range of 0–12. In order to ensure
that cats enrolled in the current study had moderate to severe activity impairments, as rated by
their owners, cats were eligible for inclusion if they received an owner-rated score of5 on
Day 0. Owners completed the CSOM without knowledge of the cut-off for inclusion.
Orthopedic Evaluation
Orthopedic evaluations were carried out as previously described,[9] and were performed by a
single veterinarian (MG) following pre-study training.[1, 7] Briefly, every joint and axial skele-
tal segment (cervical, thoracic, lumbar, and lumbo-sacral) was palpated and manipulated to
evaluate for signs of pain and instability. As described in [9], the pain response for each joint
was graded on the following scale: 0 = no resentment; 1 = mild withdrawal, mild resistance to
manipulation; 2 = moderate withdrawal, body tenses, may orient to site, may vocalize or
increase vocalization; 3 = orients to site, forcible withdrawal from manipulation, may vocalize,
hiss, or bite; and 4 = tries to escape or prevent manipulation, bites or hisses, marked guarding
of site. A total pain score was calculated as the sum of all the individual appendicular joint and
axial skeletal segment pain scores.
Radiographic Evaluation
Cats meeting eligibility criteria for owner-noted mobility/activity impairment and pain on
orthopedic evaluation were sedated using a standard protocol and orthogonal radiographs
were taken of every joint and spinal segment. Radiographs were reviewed for the presence of
degenerative joint disease as previously described [7] by a board-certified veterinary radiologist
masked to the presence or location of pain.
Randomization Method
The cats were randomly allocated to one of two treatment sequences (meloxicam followed by
placebo [PDPP Group], OR, placebo followed by meloxicam [PPPD Group]), which were
assigned to clinical cases according to predetermined randomization tables. The first period for
all cats was placebo (P), followed by either meloxicam or placebo (D or P), a masked washout
period (P), and a crossover period with either meloxicam or placebo (D or P). Randomization
was stratified by owner-rated degree of impairment based on total CSOM score. Subjects were
categorized as Low Impairment (Level 1) with total CSOM scores of 3, 4, or 5, and as High
Impairment (Level 2) with total CSOM scores of 0, 1, or 2.
Masking
NCSU-CVM Pharmacy personnel packaged meloxicam or placebo for administration to each
cat. Placebo was identical to drug, minus the active ingredient, meloxicam. Volume of drug or
placebo administered was based on the weight of the cat at D0 (enrollment). The volume of
placebo was matched to volume of drug for each cat. Packaging for drug or placebo product
was identical to prevent identification of treatment group by owners or investigators, and bot-
tles were identified only by the days they were to be administered. Individual bottles for each
period were delivered to the owner with both investigator and owner remaining masked to
treatment group.
CMIs for DJD in Cats
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Study Timeline
Cats were screened on Day 0 with owner-interview, physical, orthopedic, and neurological
examinations, radiographs, and labwork (CBC, serum biochemistry panel, urinalysis, and T4).
Eligible cats were enrolled and fitted with an activity monitor (AM; Actical Z, Philips Respiro-
nics)a worn for the duration of the study. Owners were given placebo (unmasked) at 0.07 mL/
kg/day to be given orally during the baseline period (Days 1–14). Following Day 14, all future
treatments were masked and volume-matched. Outcome measure questionnaires (described
below) were completed at regular intervals (Fig 1). During treatment periods, cats received
either placebo (0.07 ml/kg/day) or meloxicam (0.035 mg/kg/day). All cats received placebo
(0.07 mL/kg) during the masked washout period. The study design was amended to add a sec-
ond masked washout period (Days 78–99). As only 56% of enrolled cats completed this wash-
out period, data from this period are not discussed here.
Description of Outcome Measures
Safety and adverse events. Blood samples were taken from all the cats at Day 0 (baseline)
and Day 78 to evaluate any changes in CBC or serum biochemistry values over the course of
the study. Adverse events (AE) were defined as any observations in the cat that were unfavor-
able and unintended and that occurred during the study, whether or not it was considered to
be treatment related. A serious adverse event (SAE) for this study was defined as any adverse
event that was either fatal or life-threatening, required professional intervention (by a veteri-
narian) and considered by the investigators to be clinically serious or caused prolonged or per-
manent disability or disfigurement. Cats were observed throughout the study for AEs
including but not limited to: changes in appetite or thirst, vomiting, diarrhea, changes in urina-
tion or defecation frequency and consistency, negative behavioral changes, neurological signs,
lethargy or depression. Owners were asked to report any AEs at the time they occurred.
Fig 1. Study timeline and procedures completed at each timepoint.
doi:10.1371/journal.pone.0131839.g001
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Owners were given appropriate contact numbers for day or evening access to investigators in
the case of any AEs or SAEs.
Efficacy outcomes. The primary outcome measures in the study were the AM output and
the FMPI and CSOM scores. The secondary outcome measures were Change in QoL (QoL-
change), Temperament and Happiness. These owner assessments were conducted at every
time point (Days 0, 15, 36, 57, and 78).
Activity monitors. The AM and their use in cats have been previously described. [20–22]
Activity monitors were mounted on a neck collar for all cats. Collars either belonged to the cats
prior to the study, or were provided by the study for cats that did not have collars. Owners
were given the option for a harness mounted activity monitor, but no owners selected this
option. Activity monitors were set to collect data with an epoch length of 1 minute.
Owner assessments. Feline Musculoskeletal Pain Index (FMPI): This questionnaire has
been used in previous studies of cats with OA/DJD [8] and its development has been described.
[7, 9] The version of the FMPI used in the present study differed from previous versions: the
option to select ‘greater than normal’ had been deleted because previous analysis collapsed the
‘greater than normal’ and ‘normal’ category into one. The final two questions on the FMPI
were converted from a Likert scale to a visual analog scale, and questions asking about ‘overall
activity’, and overall quality of life were deleted following previous study results.[8] The FMPI
queries owners on their cat’s ability to perform each of 17 activities (rated on a Likert scale
from ‘Normal’ to ‘Not at all’) with an option to select ‘Don’t know or Not Applicable’. Two
additional items (pain domain) ask owners to rate their cat’s level of pain on a standardized
100mm visual analog scale. Owner ratings were converted to scores ranging from 0–4 for each
item with 0 = Not at all and 4 = Normal. Scores on the visual analog scale were calculated by
measuring, in mm, from the start (zero point) to the owner’s mark, with 100 indicating ‘no
pain’ and then dividing by 25 to align the scales for the entire instrument. The range of possible
scores was 0–68 for items 1–17, and 0–78 for the full FMPI. On Day 0, owners completed a
weighted FMPI (wFMPI), which asked owners to mark a visual analog scale to indicate the
importance of each activity to their cat in addition to indicating their cat’s ability on the Likert
scale. This importance scale ranged from 0 = No importance to 100 = extremely important.
Importance scores for each item were calculated by measuring, in mm, from the start (zero
point) to the owner’s mark. Client Specific Outcome Measures (CSOM) Questionnaire: As
described above, the CSOM asks owners to identify 3 activities that their specific cat is impaired
in performing, and to rate the cat’s level of difficulty in performing those activities on a Likert
scale from ‘No problem’ to ‘Impossible’. For each time point after Day 0, owners were also
asked to rate the change in their cat’s ability to perform the activity compared to before starting
the medication for that period, and these ratings were transformed into numerical scores with
Worse = -1, No Change = 0, and Improved = +1 for each activity. CSOM items were each pre-
sented in the same order for each cat at each visit.Quality of Life and Temperament Ques-
tionnaire: This assessment queried absolute Quality of Life and change in QoL, absolute
Temperament and change in Temperament, and change in Happiness. Scores from the owner
ratings were converted to numeric values as follows: QoL scores (QoL Scores) ranged from
1 = poor to 5 = excellent and a change in QoL (QoL Change) from -2 = much worse to +-
2 = greatly improved with 0 = no change in QoL; absolute temperament was a nominal scale,
while change in temperament (Temp Change) ranged from -2 = much worse to +2 = greatly
improved with 0 = no change in temperament. Happiness was rated only as change (Happiness
Change), and was converted to a score ranging from -2 = much more unhappy to 2 = much
more happy, with 0 = no change in happiness.
CMIs for DJD in Cats
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Statistical Analysis
Handling of data. Safety was analyzed for all cats enrolled in the study using Day 0 and
Day 78 labwork results and adverse events. Cats removed from the study due to AEs were
included for safety using their initial labwork, and labwork obtained at the time of the AE. Cats
removed from the study due to owner non-compliance were removed from the safety analysis
if no follow-up labwork could be obtained. For all safety analyses, data collected on Day 0 were
considered baseline. Comparisons to baseline refer to these data.
Efficacy was analyzed in both a parallel design (through Day 57) and a crossover design
(through Day 78). Cats were removed from analysis of efficacy in the parallel design if they did
not complete the study through Day 57, and from the crossover design if they did not complete
the study through Day 78. For all efficacy analyses, data collected on Day 15 were considered to
be baseline data. Stratification of the cats by CSOM score group (high impairment vs. low
impairment) was incorporated into the randomization, but results were not analyzed separately
for these strata. A p-value of 0.05 was considered significant unless otherwise noted.
Group demographics. Groups (PDPP group and PPPD group) were compared for distri-
bution of age and weight using t-tests and gender of the cats using Chi-squared analysis. Groups
were also compared on a number of environmental variables using Wilcoxon two-sample tests.
Safety. Paired t-tests were used to compare Day 0 laboratory results with end of study lab-
oratory results (Day 78 for the majority of cases, earlier if cats were withdrawn from the study
prior to Day 78). McNemar’s test was used to compare distributions on Day 0 and end of study
lab work for categorical results. Wilcoxon signed rank test was used to compare Day 0 and end
of study results for laboratory variables lacking a normal distribution (using a Kolmogorov-
Smirnov test for normality). T-tests were also used to compare end of study results between
cats in the PDPP group vs. those in the PPPD group (active medication would have ended 6
weeks prior versus 1 day prior to labwork, respectively in these groups).
Efficacy (parallel and crossover comparisons). Activity: Data points (counts) for activity
were generated at every minute of every day throughout the study. These activity counts were
averaged for each 24-hour day to generate a single data point for each cat over each day and
then the mean across a treatment period was calculated to create a single value for each cat for
each treatment period. For between group comparisons, the group average activity counts for
each day were used. These data were used for initial between group comparisons using t-tests.
Due to marked inter-cat variability in activity, activity data were then summarized for each cat
as a single value representing the average activity count per minute within a study period.
Crossover analysis of improvement for both active treatment periods was performed using
ANOVA. Paired t-tests of change in mean activity counts within each treatment group were
used to compare within group changes during the active treatment period, and during the
period following withdrawal of active treatment for the PDPP group. Paired t-tests were also
used to compare between groups for improvement in mean activity count per cat per period by
Day 36 over Day 15, and Day 78 over 57, as well as for decreases in activity counts by Day 57
over Day 36 between the PDPP and PPPD groups. FMPI: Data from the FMPI were summa-
rized by cat as both raw score (total FMPI points for Q1-17, and Q1-19), and percent possible
(%poss) score. Percent possible scores were used to adjust for the fact that some owners could
not answer all items (for example, owners without stairs indicated a Not Applicable answer for
items pertaining to stairs) and were calculated for items 1–17 and 1–19 by the following equa-
tions, respectively:




 number of questions answered  4ð Þ
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Repeatability (test-retest reliability) of the total score (for both 17 and 19 items) was evaluated
in several ways. Spearman’s rank correlation coefficients between the Day 0 scores with the
Day 15 (baseline) scores were calculated. Wilcoxon signed rank tests were used to check for
systematic differences between D0 and D15 scores (if D15 scores were consistently lower or
consistently higher than D0 scores). Bland-Altman plots were constructed to compare D0 and
D15 scores.
For the parallel design analysis, t-tests were used to analyze improvement during treatment
(raw scores and %poss scores on Day 36 minus scores on Day 15) as well as decline during the
washout period (termed “deterioration” representing a return of clinical signs following with-
drawal of previous medication; raw scores and %poss scores on Day 57 minus scores on Day
36). The FMPI was also analyzed in a success/failure paradigm and these results have been dis-
cussed elsewhere.[17]
For the crossover design analysis, improvement on Day 36 and 78 was analyzed using a gen-
eral linear model. Both raw and %poss scores were evaluated.
In addition, in an effort to refine this instrument, following analysis of a treatment effect,
we analyzed the owner-reported importance scores for each item, independence of items,
and determined which items showed significant improvement and significant deterioration
in the meloxicam treatment group during Days 15–36 and 57–78 respectively. Kruskal-
Wallace test was used to compare FMPI items related to sociability with owner-rated tem-
perament category. A Wilcoxon signed rank test was used to determine the items that
showed significant improvement at Day 36 or deterioration at Day 57, and those items that
discriminated between the PDPP sequence group and the PPPD sequence group at Day 36
and 57. CSOM: For the parallel analysis, total CSOM scores were analyzed using a Wilcoxon
rank-sum test for Day 36 (improvement) and Day 57 (deterioration). For the crossover analysis,
a general linear model was used to analyze improvement and deterioration in scores. Finally, a
success-failure analysis was performed in which the number of cats in each group with a
change in CSOM score of2 for improvement at Day 36 over Day 15, and -2 for deteriora-
tion at Day 57 over Day 36 was compared using a Fisher’s exact test and previously reported.
[17]Quality of Life, Temperament, and Happiness: For the parallel design analysis, Owner
reported change in QoL, Temperament, and Happiness was dichotomized into improved/not
(deteriorated/not) and analyzed using a generalized linear model. For analysis within the
crossover design, dichotomized results were analyzed with a generalizing estimating equation
(GEE).
Results
Enrollment and Distribution of Groups (Meloxicam-Placebo [PDPP] and
Placebo-Meloxicam [PPPD] Groups)
A total of 66 cats were enrolled in the study. All cats had lived with their owners for at least 2 ½
months (range 2 ½ months– 16 ½ years; mean 10.25 years). Adequate randomization was
achieved with no significant differences found between the groups for age, weight, or gender of
the cats (Chi-square test, all ns) (Table 1). No significant differences were found for other
demographic variables measured except for the variable “How long have you owned your cat,”
where the median number of years for the PDPP group was 12, while the median number of
years for the PPPD group was 10 (p = 0.02; Table 2). This difference, while statistically signifi-
cant, was not considered clinically significant.
CMIs for DJD in Cats
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Fig 2 outlines the flow of cats through the study following enrollment. In addition, one cat
was removed partway through the study due to development/detection of clinically relevant
hypertension with retinopathy (unrelated to study drug). Following stabilization and medical
management, this cat was re-enrolled in the study under the same case ID number. Only data
from the second enrollment were included in the analysis.
Safety and Adverse Events
Labwork analysis. No significant changes were found between Day 0 and end of study lab-
oratory results. When analyzed by final treatment (meloxicam or placebo), no significant
effects seen except in albumin, where cats that were on meloxicam days 57–78 had a signifi-
cantly higher change (decrease) in albumin from Day 0 to Day 78 (p = 0.009). There was not a
statistically significant difference in albumin values between groups on either Day 0 (p = 0.971)
or Day 78 (p = 0.084). Overall, two cats had albumin values below the normal range on Day 78,
one was mildly decreased at the start of the study, while the other moved from the normal
range to below normal (normal range 2.9 g/dL-4.0 g/dL).
Adverse events. All reported adverse events occurring in cats enrolled into the study are
summarized in Table 3. Six cats were withdrawn from the efficacy analysis prior to Day 78 due
to adverse events. Of these, four cats were withdrawn due to adverse events following meloxi-
cam administration (three cats for vomiting and one for a single seizure), and two cats were
withdrawn due to adverse events following placebo administration (one for behavioral disor-
der/hiding and one for acute kidney injury that was detected during the placebo period follow-
ing meloxicam administration). Two additional cats had clinically relevant adverse events not
reported or noted until the Day 78 exam. One cat had a mild increase in serum creatinine,
Table 1. Distribution of age, weight, and sex between treatment groups for all cats enrolled in the study.
PDPP Group PPPD Group P-value (t-test)
Variable N Mean N Mean
Age in years at start 33 12.6 33 12.5 0.93
Weight (kg) 33 5.58 33 5.63 0.90
N % Female N % Female P-value (Chi-square)
Sex 33 48% 33 50% 0.90
doi:10.1371/journal.pone.0131839.t001
Table 2. This table gives the results of Wilcoxon two-sample tests looking for differences between variables that were not controlled for in the
treatment group selection.
PDPP Group PPPD Group
Variable N Median N Median Statistic p-value
Number of people living in the house 33 2.0 33 2.0 1126.0 0.78
Number of children under the age of 10 33 0.0 33 0.0 1113.0 0.90
Number of people gone for more than four hours a day 32 1.5 32 1.0 1072.5 0.65
How long have you owned the cat? (years) 33 12.0 33 10.0 905.0 0.01
Number of pets in the house 33 4.0 33 3.0 1066.0 0.61
Number of cats in the house 33 3.0 33 3.0 1161.5 0.47
Number of dogs in the house 33 0.0 33 0.0 1037.5 0.31
Size of house (square feet) 33 2000.0 31 2400.0 1125.0 0.16
Percent of house access for cat 33 100.0 33 100.0 1050.0 0.43
Height easily jumped to (inches) 33 24.0 31 18.0 938.0 0.35
doi:10.1371/journal.pone.0131839.t002
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while the other had been vomiting for several days prior to examination, and had a marked
increase in serum creatinine requiring fluid therapy and hospitalization. These cats were with-
drawn from the study with respect to efficacy analysis but are represented in the safety analysis.
Efficacy
Actimetry. When data were averaged across cats, by day and treatment, significant differ-
ences between the treatment groups were found for Days 15–36 (first treatment period;
t = 17.7, p<0.0001) Days 37–56 (t = 7.22, p<0.0001), and Days 56–78 (second treatment
period; t = -2.35, p = 0.0235).
Analysis of individual cat patterns of activity counts revealed marked inter-cat variability
(Fig 3), suggesting that between group analyses may be less appropriate than within group
analyses. The coefficient of variation between cats for the AM data during the baseline period
was 50%. For remaining analyses, activity data were summarized as average counts per minute
across each treatment period, with one value describing each cat for a given period. Using these
data from the baseline period (Days 1–15) and the two treatment periods (Days 16–36 and
Days 57–78), there was a strong treatment effect (p<0.0001, ANOVA) and a weak time and
sequence effect (p = 0.088 and p = 0.081 respectively). Cats had increased activity counts when
receiving meloxicam, and activity counts tended to be higher during the first treatment period
than the second, and higher in the PDPP versus PPPD sequence cohort (Table 4).
Within group comparisons are summarized in Table 5, and show a non-significant increase
in activity counts (p = 0.31) when meloxicam was administered, but a significant decrease in
activity counts (p = 0.0008) when active medication is withdrawn in the PDPP cohort. The
PPPD cohort showed a significant increase in activity counts when administered meloxicam
(p = 0.0134), and no change from baseline to placebo, or placebo to placebo.
Comparing between groups for change (improvement) from baseline to the end of period 1,
there was no difference between the cats receiving meloxicam in period 1 and those receiving
placebo (p = 0.53), with both groups increasing in activity counts slightly (Table 6). However,
Fig 2. Participant flow diagram. Events occurring at each time point are outlined below. Cats removed from the efficacy analysis were retained for the
safety analysis, unless otherwise noted. Cats are designated by the group they were part of (PDPP [meloxicam first] or PPPD [placebo first]).
doi:10.1371/journal.pone.0131839.g002
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cats that had received meloxicam during the first period showed a more significant decrease in
activity counts during the masked washout (period 3) than the cats that had received placebo
in the first period (p = 0.019).
Feline Musculoskeletal Pain Index (FMPI). Correlations between D0 and D15 scores for
the FMPI with 17 and 19 items were moderately strong (rs = 0.72 and rs = 0.73, respectively).
The difference between the means was small (1.55 for the FMPI with 17 items, and 1.57 for the
FMPI with 19 items), however Day 15 scores were significantly higher (indicating less
impairment) than D0 scores for total FMPI with 17 items (S = 268.5, p = 0.031) and total FMPI
with 19 items (S = 249.0, p = 0.041). Bland-Altman plots of the D0 and D15 data showed that
there were 2 outliers, both cats belonged to same owner. The plots show the majority of cats
were scored as being less impaired on D15 compared to D0. There was no obvious association
Table 3. Summary of adverse events reported by owners during the course of the study.
Adverse Event Placebo (number of cats with
sign)/Number of cats
removed
Meloxicam (number of cats with
sign)/Number of cats removed
Cats removed from study prior to
Day78 predominantly due to this AE
Gastrointestinal signs
Vomiting 11/0 8/3 3
Diarrhea 2 2 0
Regurgitation 1 0 0
Flatulence 0 1 0
Loose stool 1 0 0
Constipation 1 0 0
Behavioral/Neurologic signs
Head tilt* 1 1 0
Behavioral disorder not otherwise
specified
2/1 1/0 1
Seizure 0/0 1/1 1
Urinary/Renal signs
Nephritis 0 1 NA (end of study)
Acute Kidney Injury 1/1 1/0 1 (1 end of study)
Renal insufficiency 1 1 0
Urinary tract infection 2 0 0
Other Systemic Disorder
Elevated ALT 0 1 NA (end of study)
Hypertension 0 1 0
Diabetes 1 0 NA (end of study)
Weight loss 1 0 0
Other labwork abnormalities 2 1 0
Other
Skin lesion 0 2 0
Musculoskeletal disorder (owner
concerned about antebrachial swelling)
1 0 0
Nasal discharge/sinus disorder 1 0 0
Aural discharge/infection 0 1 0
Listed are the number of cats with each sign while on placebo and while on meloxicam treatment. In addition, for any adverse event where cats were
removed from the study prior to Day78 predominantly due to this AE, the number of cats removed from each group is listed.
* In one case (placebo), the head tilt was transient, in the other case (meloxicam), the head tilt was associated with severe otitis media.
doi:10.1371/journal.pone.0131839.t003
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between increasing score and an increase or decrease in scatter (Fig 4A and 4B). All points
except the 2 outliers lay within +/- 2SDs of the difference.
Results for the parallel analysis are shown in Table 7. A significant difference (p = 0.048) in
percent possible scores (for items 1–17) was found for deterioration, with the cats that had
been on meloxicam during Days 15–36 showing a greater deterioration in %possible scores
than the cats that had been on placebo. When raw scores (total of items 1–17 without account-
ing for percent possible) were compared, no differences between the groups were found for
improvement at Day 36 or deterioration at Day 57.
Both percent possible and raw scores were evaluated in a general linear model for improve-
ment on Day 36 and 78 for the crossover analysis, results are shown in Table 8. Deterioration
was not evaluated for the crossover as not all cats had a matched post-treatment washout
period (Day 99). Percent possible was evaluated for both FMPI Q1-17 and FMPI Q1-19. A sta-
tistically significant treatment effect for improvement in percent of possible points was found
Fig 3. Plots of mean activity counts per day for individual cats in the PDPP (meloxicam first) and
PPPD (placebo first) groups. These plots highlight the marked inter-cat variability in activity seen
throughout the study.
doi:10.1371/journal.pone.0131839.g003
Table 4. Summary of analysis of variance of average activity counts per minute per period and least-squares means from the crossover analysis.
Source Numerator DF Denominator DF Type III Sum of Squares F Value Pr > F
Treatment 1 52 532.3 20.21 <0.0001
Time 1 52 79.5 3.02 0.088
Sequence 1 94.2 129.6 2.18 0.081
Previous Activity 1 52 48.2 1.83 0.182
Variable Level Least Squares Mean
Treatment Meloxicam 36.2
Placebo 31.8




Averaging by cat across each period allows for a crossover analysis of improvement for both treatment periods.
doi:10.1371/journal.pone.0131839.t004
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for both 17 and 19 items (meloxicam treated cats had greater improvement than placebo
treated cats), however the effect appeared to be stronger for the 17 items. Evaluation of raw
scores for FMPI Q1-17 showed an improvement in meloxicam treated cats over placebo treated
cats that was significant at the 10-percent level.
There was no significant relationship between average activity count over the baseline
period and Day 15 CSOM score (R2 = 0.042; P = 0.124) or Day 15 FMPI Score expressed as %
possible (R2 = 0.034; P = 0.166) (Fig 5A and 5B).
Analysis of owner-rated importance scores showed high variability in responses. Impor-
tance scores relative to the overall median importance score across all respondents and all
items indicated that items 1, 6, 7, 10, 11, 13, 14, 15, 16, and 17 were rated as relatively important
to cats by owners of cats in the study. These items included questions about their cat’s ability to
walk, go up and down stairs, and eat among others. Using these items alone did not detect
improvement or deterioration. The items that detected significant improvement at Day 36 fol-
lowing meloxicam treatment were 3, 5, 6, 7, 8, 9, 10, 12, 15, 17, 18, and 19. Items that detected
significant deterioration following meloxicam administration at Day 57 were items 9, 10, and
11. However, the only items that were able to discriminate between meloxicam and placebo at
Day 36 (greater improvement in the meloxicam group) were items 1 (p = 0.019), 12
(p = 0.089), and 14 (p = 0.022), while those able to discriminate between withdrawal of meloxi-
cam and withdrawal of placebo at Day 57 (greater deterioration in the cats that had moved
from meloxicam to placebo) were items 10 (p = 0.018), 11 (p = 0.006), 12 (p = 0.030), and 16
(p = 0.060).
Client Specific Outcome Measures (CSOM). For the parallel design, we first calculated
Wilcoxon rank-sums tests for improvement of total CSOM scores on Days 36 (improvement)
and 57 (deterioration). No statistically significant differences were found between the meloxi-
cam group and the placebo group in this analysis. For the crossover design, we used a general
Table 5. Within group comparisons of activity data between periods.
Group: PDPP Mean Difference Std. Dev. T-statistic P-value
Days 15 to 36 –Days 1 to 15 1.3284 6.8628 1.04 0.3061
Days 37 to 56 –Days 15 to 36 -4.2448 6.1081 -3.74 0.0008
Days 57 to 78 –Days 37 to 56 -1.9101 4.9203 -2.09 0.0458
Group: PPPD
Days 15 to 36 –Days 1 to 15 0.3497 4.8837 0.39 0.7027
Days 37 to 56 –Days 15 to 36 -0.3653 6.1219 -0.32 0.7503
Days 57 to 78 –Days 37 to 56 2.9776 5.9542 2.65 0.0134
Results from paired t-tests of change in mean activity counts for each cat within each treatment group, Days 1 to 15 versus Days 16 to 36, Days 37 to 56
versus Days 57 to 78. A positive result indicates higher activity counts during the later time period.
doi:10.1371/journal.pone.0131839.t005
Table 6. Between group differences in change in activity counts over the first treatment period and subsequent masked washout period.
Group Mean (SD) t-statistic p-value
Improvement (Day 36 –Day 15) PDPP 1.33 (6.86) 0.63 0.534
PPPD 0.35 (4.88)
Deterioration (Day 57 –Day 36) PDPP -4.25 (6.11) -2.42 0.019
PPPD -0.37 (6.12)
Data are averaged across days by cat.
doi:10.1371/journal.pone.0131839.t006
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linear model to analyze improvement in total CSOM scores and change in CSOM scores. In
this model, there was a statistically significant time effect for change in total score (owners are
more likely to report improvement at Day 36 than at Day 78) but no significant treatment
effect (Table 9).
Quality of Life, Temperament, and Happiness Questionnaire. For the parallel design,
we looked at owner reported changes in QoL, Temperament, and Happiness at Day 36 (vs.
Day 15) and Day 57 (vs. Day 36) for improvement from baseline, and deterioration from Day
36 levels, respectively. No statistically significant changes were found (Table 10). The deteriora-
tion in Happiness was significant at the 10-percent level, more cats that had received meloxi-
cam during Days 15–36 had a decrease in Happiness at Day 57 than the cats that had received
placebo during Days 15–36.
Fig 4. Bland-Altman plots of the FMPI for 17 items (A) and 19 items (B).
doi:10.1371/journal.pone.0131839.g004
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When evaluating owner reported scores rather than owner reported change for QoL, there
were no significant differences between groups for Day 36-Day 15 scores (improvement) or
Day 57-Day 36 scores (deterioration).
For the crossover design, analysis of owner reported change in QoL, Temperament, and
Happiness using a GEE analysis found a significant time effect for QoL (p = 0.017) such that
owners were more likely to report improvement in QoL at Day 36 than at Day 78, regardless of
treatment. No other significant effects were found for improvement.
Table 7. Summary of group comparisons of improvement / deterioration in the percent of possible points on the full FMPI questionnaire (Items
1–19), percent of possible points on Items 1–17 from the FMPI questionnaire, and improvement / deterioration in raw scores (Items 1–17) between
Day 36 and Day 15 / between Day 36 and Day 57 respectively.
PDPP PPPD T-test
FMPI Q1-Q19: Percent Possible Mean Std.Dev. Mean Std.Dev. T-statistic p-value
Improvement, Day 36 –Day 15 0.107 0.106 0.100 0.100 0.26 0.794
Deterioration, Day 57 –Day 36 -0.056 0.121 -0.001 0.126 -1.69 0.097
FMPI Q1-Q17: Percent Possible
Improvement, Day 36 –Day 15 0.102 0.105 0.092 0.101 0.38 0.706
Deterioration, Day 57 –Day 36 -0.055 0.113 0.006 0.118 -2.03 0.048
FMPI Q1-Q17: Raw Scores
Improvement, Day 36 –Day 15 6.379 7.063 6.379 6.769 0.00 1.000
Deterioration, Day 57 –Day 36 -3.414 7.765 -0.276 7.695 -1.54 0.130
doi:10.1371/journal.pone.0131839.t007
Table 8. Summary of general linear model analysis of improvement in the percent of possible points
on the FMPI questionnaire (Items 1–19 and 1–17) and improvement in raw scores (Items 1–17) on Day
36 and Day 78.
Improvement (Day 36 and Day 78)
FMPI Q1-Q19; Improvement in Percent Possible
Source DF F Value Pr > F
Treatment 1 4.72 0.034
Time 1 1.01 0.318
Sequence 1 0.00 0.952
Error 54
Corrected Total 111
FMPI Q1-Q17; Improvement in Percent Possible
Source DF F Value Pr > F
Treatment 1 6.07 0.017
Time 1 1.09 0.301
Sequence 1 0.02 0.882
Error 54
Corrected Total 111
FMPI Q1-Q17; Improvement in Raw Scores
Source DF F Value Pr > F
Treatment 1 3.30 0.075
Time 1 0.58 0.451
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Discussion
With activity monitor counts used as our reference standard, we saw a significant treatment
effect of low-dose oral meloxicam in increasing activity counts in cats with degenerative joint
disease. Significantly higher levels of activity were detected in the meloxicam treated cats dur-
ing the treatment periods. Inter-cat variability in activity counts were high. This is likely to be
mainly due to differences in activity between cats, though reasons for these differences are
unknown. Potential sources of variability include indoor vs. indoor/outdoor status, presence of
stairs or size of home, and day of the week, as well as age, impairment, weight, and other fac-
tors. In this study, we restricted enrollment to cats that were indoors only, as indoor/outdoor
cats have been shown to have different activity patterns, particularly if outside overnight.[23]
This also decreases the effect that outside weather would have on activity. All cats in the study
had approximately the same number of week and weekend days included in the analysis, and
Fig 5. Relationship between average activity count and CSOM score at Day 15 (A) and FMPI %poss
score at Day 15 (B).
doi:10.1371/journal.pone.0131839.g005
Table 9. Summary of general linear model analysis of improvement / deterioration in the total score across all three CSOMmeasures on Day 36
and Day 78 / on Day 57 and Day 99 respectively as well as change in total score.
Source D.F. F-Value P-value
Total Score, Day 36 and Day 78 Time (Day 36 and 78) 1 0.26 0.612
Treatment (Meloxicam vs. Placebo) 1 0.62 0.433
Sequence 1 0.37 0.544
Change in Total Score (Day 36 –Day 15, Day 78 –Day 57) Time (Day 36 and 78) 1 23.09 <0.001
Treatment (Meloxicam vs. Placebo) 1 0.06 0.814
Sequence 1 0.03 0.862
Change was calculated as Day 36 –Day15, and Day 57 –Day 36.
doi:10.1371/journal.pone.0131839.t009
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other factors were shown to be similar between groups of cats, so while these might contribute
to individual variability, they were evenly distributed between treatment groups. In addition,
recent data from our laboratory (Hansen, unpublished data) indicates that the output from dif-
ferent accelerometers can vary significantly (although each is stable over time), suggesting cau-
tion be exercised when comparing data between accelerometers. Considering both these
aspects, we therefore consider within group comparisons more appropriate. When evaluating
intra-cat/intra-group changes we found a significant treatment effect where meloxicam
increased activity counts in cats with DJD. Further, we saw a significant deterioration in activ-
ity counts during the period following withdrawal of active medication in the PDPP sequence
group. The same analysis was not available for all cats in the PPPD group. Other studies using
meloxicam in cats with DJD or osteoarthritis have found similar treatment effects with meloxi-
cam on improvement of activity counts.[8] Two studies using client-owned cats found that
daily administration of meloxicam led to increased daily activity counts. In these studies, cats
were selected based on owner-noted mobility impairment, and veterinary diagnosis of degener-
ative joint disease, and cats were maintained in their home environment throughout the study.
Using laboratory housed cats, Guillot et al found that night time activity counts were higher in
normal (non-arthritic) cats than in OA cats,[24] and later found that night-time activity counts
increased in cats on meloxicam at 0.025 mg/kg and 0.05 mg/kg daily, though not in the cats
receiving meloxicam at 0.04 mg/kg/day.[25]
The current study detected differences between cats receiving meloxicam vs. placebo using
subjective measures of owner report captured with the FMPI. The FMPI was developed using
appropriate methods.[7–9] In previous work, the FMPI was shown to have discriminatory
validity,[7] and good repeatability (test-re-test reliability).[7] However, in the present study
using cats with higher impairment, repeatability was not as good. In the present study,
although test-retest reliability of the FMPI instrument was reasonable, scores on Day 15 were
significantly higher than on Day 0. Although the actual difference in number of points was
small, this indicates that owners are rating their cats as significantly less impaired on Day 15
following a 2-week period of known placebo administration. We believe this justifies the use of
the Day 15 scores as the baseline. The period from Day 0-Day 15 may serve as a learning period
for the owners as well as a chance for owners to better observe the behavior of their cats. By
requesting owners to give a daily medication (in the exact same manner as in the masked por-
tion of the study) we likely changed the observation of cats by owners, and perhaps also altered
the behavior of the cat, which might explain some of the differences in repeatability found in
the present study. The present study also included a new analysis, the percent possible calcula-
tion for the FMPI, as well as enrolling more cats than the previous evaluation of the FMPI.
As has been described for dogs with osteoarthritis [26], we also observed a sizeable caregiver
placebo effect in owner reports during the first treatment period. Using the analysis of the per-
cent possible score for the 17-item FMPI (excluding the two VAS scale items), this instrument
is able to detect improvement in the crossover design, but not in the parallel design due to the
Table 10. Improvement in owner reported Change for Quality of Life, Temperament, and Happiness at Day 36 (from Day 15) and deterioration in
owner reported Change for Quality of Life, Temperament, and Happiness at Day 57 (fromDay 36).
Improvement at Day 36 Deterioration at Day 57
Effect Chi-Square p-value Effect Chi-Square p-value
Quality of Life 1.02 0.313 Quality of Life 1.27 0.259
Temperament 0.67 0.412 Temperament 0.42 0.518
Happiness 0.09 0.764 Happiness 2.98 0.084
doi:10.1371/journal.pone.0131839.t010
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caregiver placebo effect. This suggests that one way to adjust for the initial caregiver placebo
effect is to use a crossover study design. Using the full cross-over design allowed for a difference
between groups to be detected in objective actimetry during the second treatment phase. How-
ever, the full cross-over design creates a long, cumbersome clinical study. There are few
masked, placebo controlled clinical studies assessing pain relief in client-owned cats with
chronic pain [8, 15, 27] and large placebo effects have been seen in these studies as well.
Although it has not been evaluated in detail, the placebo effect in these studies appears larger
than is seen in comparable canine studies. This could be due to a lack of specificity in the CMI,
or could be due to owners expectation of a positive effect combined with an overall lack of
awareness of owners to their cat’s behaviors. Study design may also be improved by better
training of owners to recognize signs of pain in their cats, particularly those that are most
responsive to analgesics.
The use of a percent possible score for the 17-item FMPI was also able to detect a deteriora-
tion following withdrawal of active medication that is not seen with the withdrawal of placebo.
This effect can also be seen with a success/failure paradigm for the FMPI and CSOM (though
selection of threshold for the FMPI may require further evaluation).[17] These data parallel the
decrease in activity counts seen when active medication is withdrawn. Interestingly, though
only significant at the 10% level, owner ratings of cat happiness also show the deterioration
effect following the masked washout. Our measures of temperament and quality of life, and
change in temperament and quality of life did not detect the presumed efficacy of meloxicam,
despite previous work indicating strong relationships between the presence of DJD and both
temperament [3, 8, 28] and quality of life.[7, 29]
Return of clinical signs following randomized withdrawal of active medication is a clinical
trial design that has been used in humans, however, to our knowledge, all studies using this
approach fall into the category ‘Enriched Enrollment, Randomized Withdrawal’ (EERW).[30–
32] EERW designs select for treatment responders at the start of study, followed by randomiza-
tion to continuation of the treatment or a switch to a placebo or active control to measure effi-
cacy. These studies may then compare the treatment to the placebo/active control. One
complaint about this design is the length of time required for the study.[32] Our study design
did not select for treatment responders, and we refer to our design using randomized allocation
and withdrawal as the ‘RAW’ design. We believe RAW designed clinical trials may be very use-
ful in evaluating analgesics for chronic pain management in cats, both for placebo controlled as
well as analgesic comparison studies.[33] While replication is necessary, if effective, this study
design provides for shorter study duration, and less cumbersome clinical trials.
Owner ratings of item importance for the FMPI were not fully indicative of the items in
which improvement or deterioration were seen, or those where a difference was detected
between meloxicam and placebo. Future work will investigate whether owner ratings of impor-
tance can be used to give weight to individual FMPI questions for individual owners, or used to
refine the structure of the FMPI. One important consideration when considering refinements
or modifications to the FMPI is the effect of the order of the questions, or whether particular
questions are important in encouraging respondents to reflect on their cat’s behavior. The first
step in selection of questions for an abbreviated FMPI would be to compare administration of
the full instrument, with a priori decision to analyze only a subset of items, with a shortened
form. Interestingly, while the FMPI, as percent possible, was able to detect a treatment effect,
only one question, asking about the cat’s ability to stretch, distinguished between meloxicam
and placebo in both the treatment and deterioration phase, and this was only if one accepted a
p-value at the 10% level for the treatment phase. However, there was no significant relationship
between baseline scores of ability to stretch and baseline activity counts, despite the fact that
AM data was also able to detect treatment effects and the effects of treatment withdrawal.
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Previous studies with cats have looked at behavioral domains or specific behaviors that are
responsive to analgesic treatment. A study by Clarke and Bennett showed owner ratings of
improvement in willingness to jump, height of jump, and gait stiffness in cats with osteoarthri-
tis that received meloxicam.[34] A second study by Bennett and Morton using meloxicam in
cats with osteoarthritis found that owners rated positive changes in their cats in mobility,
grooming habits, and temperament, with the greatest positive change in activity, though no
placebo group was included for comparison.[28] A study by Klinck et al. used a survey to inves-
tigate, among others, additional signs for OA detection and monitoring in cats based on own-
ers’ observations.[3] This study found that owners reported changes in several specific
behaviors, with jumping, stair use, and alterations in gait being present in75% of cats with
OA. In addition, owners reported that jumping, stair use, speed, gait, mood, activity level, and
daily schedule were perceived as responsive to treatment in50% of the OA-affected cats.
Future work should consider gathering video data on cats in the home environment, before
and after treatment, and creating detailed ethograms of what behaviors are performed and
change, as well as owner input on the changes they detected. This information may then form
the basis of developing the next generation of CMIs.
Our data indicates that the incorporation of the final two questions on the FMPI (asking
about pain levels over the last 3 weeks, and pain levels today) did not improve the sensitivity of
the FMPI, and our current recommendations are that these are dropped from the instrument.
We believe these changes can be made without further evaluation because they were the last 2
questions on the FMPI and so deleting them will not influence how earlier questions are
answered.
Additional objective measures could also be incorporated into the management of cats with
DJD, as well as for further development and validation of CMIs. Several objective measurement
systems have been tested in cats, including peak vertical ground force reaction [24, 25, 35] and
goniometry.[6] In particular, peak vertical ground force reaction (PVF) has been shown to be
moderately feasible in client-owned cats (8/23 cats refused to traverse the walkway),[35] and
able to distinguish between normal cats and those with DJD [24], but was not able to show a
treatment effect for meloxicam in cats with DJD.[25] This measure was not included in the
present study, however, it is possible that complementary measures to actimetry would allow
for increased sensitivity in the refinement of CMIs.
Finally, we have suggested that the data from Day 99 might not be as useful as data gathered
earlier in the study. There are several reasons for this observation, including the smaller num-
ber of cats completing this time point. We found clinician impressions that owners were
experiencing study fatigue, and were not as diligent in completing their surveys during this
final evaluation. In addition, to remain in line with the earlier study protocol, the cats them-
selves had their final appointments on Day 78, and labwork/physical exam findings had already
been discussed. It is our feeling that the final masked washout period may have occurred after
the study had almost “ended” in the minds of the owners, despite the investigators informing
them that a further treatment period, which could be active medication or placebo, occurred
during days 78–99.
In this study, we used the NSAID meloxicam as our therapeutic intervention. The low-dose
of meloxicam used was generally tolerated well by most cats, and can be regarded as efficacious
in the management of DJD-associated chronic pain. This study enrolled cats with mild-moder-
ate renal insufficiency and, as reported in Gowan,[14] overall changes in creatinine and blood
urea nitrogen were not observed. While the cats in the PPPD group had a higher decrease in
albumin from Day 0 to Day 78 than those in the PDPP group, this is of unknown clinical sig-
nificance in the absence of other changes. The number of cats showing vomiting were fairly
evenly distributed to active and placebo treatments. However, rates of adverse renal effects
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including acute kidney injury were higher during or immediately following meloxicam admin-
istration than following placebo administration, warranting further investigation. In the most
extreme case, a cat on meloxicam was vomiting for several days prior to the owner reporting
this to investigators. It is not known, but is supposed, that earlier intervention would have miti-
gated the extent of this cat’s kidney injury, as meloxicam is tolerated fairly well by cats with
chronic kidney disease that maintain euvolemia.[36] Given the therapeutic effectiveness of this
medication, more sensitive early markers of injury, or screening tests able to predict tolerance
of this class of drug would be of high value. This is especially important as recent work has
shown that the overlap of DJD and CKD is great.[37]
Conclusions
In conclusion, when evaluating treatments for DJD-associated chronic pain, we recommend a
masked, parallel study design, which incorporates a masked washout period to allow for the
assessment of deterioration (RAW design), and use of actimetry as a reference standard. We
recommend the use of actimetry only for within group paired comparisons, and comparisons
between groups in the degree of change. Actimetry values are too variable from cat to cat to
allow for direct between group comparisons. Additionally, we recommend the use of the
17-item FMPI, expressed as a percent of possible, to detect deterioration. Finally, we recom-
mend the use of success/failure criteria for the FMPI to detect deterioration, or the use of suc-
cess/failure criteria for the CSOM to detect deterioration.
a Actical, Philips Respironics, Bend, Oregon, USA
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